Nintedanib esylate



CAS
656247-18-6

Inquiry

Nintedanib esylate belongs to the group of tyrosine kinase inhibitors and angiokinase inhibitors. The active ingredient slows down the formation of blood vessels, which is increasingly common in carcinomas. It is used to treat bronchial carcinomas and pulmonary fibrosis.

Description

Formula	$C_{33}H_{39}N_5O_7S$
Molecular weight	649.76 g/mol
Molecular size	small
Controlled Substance	no
Precursor	no
Indications	Antineoplastic drugs

Midas Pharma GmbH - Rheinstr. 49 - 55218 Ingelheim - Germany
phone +49 6132 990-0 - fax +49 6132 990-40 - info@midas-pharma.com
© 2024 Midas Pharma GmbH. All Rights Reserved.

Your Contact

Marius Hang

International Division

Director API Export

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
Send E-Mail

Disclaimer

The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.

© 2024 Midas Pharma GmbH. All Rights Reserved.